Impact of recommendations on the initial therapy of Parkinson’s disease: A population-based study in France
Copyright policy )Impact of recommendations on the initial therapy of Parkinson’s disease: A population-based study in France
Levodopa induces long-term motor complications in Parkinson's disease (PD). Therapeutic strategies that prevent motor complications are needed. Our aim was to evaluate the impact of recommendations of a French consensus conference published in 2000 on initial PD therapy. We identified 308 PD patients as part of a population-based study performed within the Mutualité Sociale Agricole in five French districts (2007). Neurologists confirmed PD diagnosis. We compared initial therapy in 102 patients treated before 12/31/2000 to that of 206 patients treated afterwards. Initial treatment was in agreement with the recommendations if dopamine agonists were used in patients <60 years (n = 49) and levodopa in patients ≥70 years (n = 133). Agreement with the recommendations increased after 2000 (66.0%) compared to before (46.3%, p = 0.025). For patients <60 years, agreement increased (64.0% vs 20.2%, p = 0.017) while it remained stable (66.4% vs 70.6%, p = 0.73) in patients ≥70 years. The publication of recommendations has influenced initial treatment choices for PD in France.
Male, Epidemiology, Parkinson's disease, Consensus Development Conferences as Topic, MESH: Antiparkinson Agents, 610, Guidelines, Antiparkinson Agents, Levodopa, MESH: Practice Guidelines as Topic, 616, Medical practice, Humans, Practice Patterns, Physicians', MESH: Physician's Practice Patterns, MESH: Dopamine Agonists, Aged, MESH: Aged, MESH: Levodopa, MESH: Humans, MESH: Middle Aged, MESH: Consensus Development Conferences as Topic, Parkinson Disease, Middle Aged, MESH: Male, MESH: France, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Guideline Adherence, Dopamine Agonists, Practice Guidelines as Topic, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Female, France, Guideline Adherence, MESH: Female, MESH: Parkinson Disease
Male, Epidemiology, Parkinson's disease, Consensus Development Conferences as Topic, MESH: Antiparkinson Agents, 610, Guidelines, Antiparkinson Agents, Levodopa, MESH: Practice Guidelines as Topic, 616, Medical practice, Humans, Practice Patterns, Physicians', MESH: Physician's Practice Patterns, MESH: Dopamine Agonists, Aged, MESH: Aged, MESH: Levodopa, MESH: Humans, MESH: Middle Aged, MESH: Consensus Development Conferences as Topic, Parkinson Disease, Middle Aged, MESH: Male, MESH: France, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Guideline Adherence, Dopamine Agonists, Practice Guidelines as Topic, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Female, France, Guideline Adherence, MESH: Female, MESH: Parkinson Disease
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).17 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!